Access to anti-retroviral drugs, male in Libya

Libya: Access to anti-retroviral drugs, male was 49.0% in 2023. ▲ Rising

Latest (2023)
49.0%
Change on year
up 4.3%
World rank
119th
of 141 countries
All-time high
77.0%
in 2018
All-time low
17.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, male in Libya, 2000–2023

204060802000201120232000: 17 %2001: 19 %2002: 22 %2003: 18 %2004: 25 %2005: 29 %2006: 32 %2007: 37 %2008: 42 %2009: 49 %2010: 53 %2011: 60 %2012: 62 %2013: 61 %2014: 64 %2015: 68 %2016: 70 %2017: 71 %2018: 77 %2019: 53 %2020: 48 %2021: 47 %2022: 47 %2023: 49 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2023, access to anti-retroviral drugs, male in Libya stood at 49.0%.

The figure is up 4.3% on the previous year and down 19.7% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Libya peaked at 77.0% in 2018 and was at its lowest, 17.0%, in 2000.

Libya ranks 119th of 141 countries on this measure, in the bottom quarter.

The long-run direction has been consistently rising across the 24 years of available data.

Access to anti-retroviral drugs, male in Libya, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Libya, 2000 to 2023.
Year % Change
2000 17.0%
2001 19.0% +11.8%
2002 22.0% +15.8%
2003 18.0% -18.2%
2004 25.0% +38.9%
2005 29.0% +16.0%
2006 32.0% +10.3%
2007 37.0% +15.6%
2008 42.0% +13.5%
2009 49.0% +16.7%
2010 53.0% +8.2%
2011 60.0% +13.2%
2012 62.0% +3.3%
2013 61.0% -1.6%
2014 64.0% +4.9%
2015 68.0% +6.2%
2016 70.0% +2.9%
2017 71.0% +1.4%
2018 77.0% +8.5%
2019 53.0% -31.2%
2020 48.0% -9.4%
2021 47.0% -2.1%
2022 47.0% +0.0%
2023 49.0% +4.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 29.0% 17.0% 49.0% 10
2010s 63.9% 53.0% 77.0% 10
2020s 47.8% 47.0% 49.0% 4

Countries ranked near Libya

  1. 116 Latvia 51.0% compare
  2. 117 Lithuania 50.0% compare
  3. 117 Papua New Guinea 50.0% compare
  4. 120 Belize 48.0% compare
  5. 120 Kyrgyzstan 48.0% compare
  6. 122 Jamaica 47.0% compare
  7. 122 Republic of Moldova 47.0% compare
  8. 122 Qatar 47.0% compare

See the full ranking of 160 places →

More gender data for Libya

All data for Libya →

Frequently asked questions

What is access to anti-retroviral drugs, male in Libya?
Access to anti-retroviral drugs, male in Libya was 49.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Libya?
The highest recorded value was 77.0% in 2018.
What is the lowest access to anti-retroviral drugs, male recorded in Libya?
The lowest recorded value was 17.0% in 2000.
How does Libya rank for access to anti-retroviral drugs, male?
Libya ranks 119th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, male rising or falling in Libya?
Over the last ten years it is down 19.7%. The long-run trend across the full record is rising.
Where does this Libya data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Libya. Statizoid, drawing on UNAIDS estimates. Retrieved 04 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/libya/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/libya/">Access to anti-retroviral drugs, male in Libya</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.